Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SimpliMax Dual Layer Amniotic Membrane is a medical device derived from human amniotic membrane, specifically engineered as a dual-layer graft. The amniotic membrane consists of two conjoined layers—the amnion and chorion—harvested from the innermost lining of the placenta. This product is used primarily as a biological dressing to promote wound healing, reduce inflammation, minimize scarring, and provide anti-bacterial and anti-fibrotic effects. Its mechanism of action involves delivering high concentrations of cytokines and growth factors that support epithelial cell migration, adhesion, differentiation, inhibit fibroblast proliferation (thus reducing scar formation), block angiogenesis, and provide antimicrobial protection. The dual-layer design may enhance structural integrity or handling characteristics for clinical use in ophthalmology (e.g., corneal or conjunctival defects) or other surgical/regenerative applications[1][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SimpliMax Dual Layer Amniotic Membrane.